HPV-literate population 

As Guyana observes International HPV Awareness Day, the call for intensified public education and expanded access to prevention and treatment services arrives at a decisive moment in the national health agenda. Cervical cancer remains one of the most preventable forms of cancer, yet it continues to claim lives at a rate that underscores the urgent need for sustained, coordinated action. The pathway to elimination is neither speculative nor unattainable. It is clearly mapped through vaccination, screening, early detection and comprehensive treatment.
The work of the Presidential Commission on the Prevention and Control of the NCDs has placed renewed emphasis on building an HPV-literate population. Human papillomavirus is not a distant or abstract medical concern; it is a common infection with well-established links to cervical cancer, particularly high-risk strains such as HPV 16 and HPV 18. More than 90 per cent of cervical cancers are associated with a small cluster of these high-risk types. Public understanding of this connection is essential, and awareness shapes behaviour, and behaviour determines uptake of vaccines, screening and treatment.
The data are sobering. Cervical cancer remains the second most common cancer affecting women in Guyana. With approximately 121 new cases and 63 deaths annually, the disease exerts a disproportionate burden on women between the ages of 15 and 44. An incidence rate exceeding 20 per 100,000 women places Guyana among countries with high prevalence. By contrast, the benchmark for elimination set by the World Health Organization is fewer than four cases per 100,000 women. The gap between current reality and that target is substantial, but it is not insurmountable.
National policy has already embraced the pillars required to close that gap, as free HPV testing represents a critical intervention, particularly when coupled with the maintenance of a national register to monitor HPV-positive individuals and ensure timely follow-up. Screening targets – 70 per cent of women tested by age 35 and again by age 45 by 2030 – align with global standards and reflect an evidence-based approach. Screening identifies pre-cancerous changes long before they develop into invasive disease. Early detection not only saves lives but also reduces the long-term financial and social costs associated with advanced cancer care.
Since the introduction of the HPV vaccine in 2010, the programme has expanded to include both girls and boys between the ages of nine and 15. Current coverage exceeding 60 per cent represents measurable progress, yet the 90 per cent target by 2030 demands intensified outreach and community engagement. The use of the Gardasil 9 vaccine, which protects against nine HPV strains, positions Guyana among a limited number of developing countries utilising this advanced formulation. That decision reflects a strategic investment in long-term disease reduction.
Globally, momentum toward cervical cancer elimination has accelerated, as since 2017, 71 countries had incorporated HPV vaccines into national immunisation programmes; by the end of 2023, 143 had done so. However, disparities remain stark. High Human Development Index countries report vaccination rates as high as 77 per cent, while lower-HDI regions lag significantly behind. International statistics reveal approximately 600,000 new cervical cancer cases and 338,800 deaths each year, with mortality rates in low-HDI countries six times higher than in high-HDI nations. These inequities highlight the broader intersection between public health capacity and socio-economic development.
The adoption of the Global Strategy for Cervical Cancer Elimination by the World Health Organization in November 2020 formalised the “90-70-90” targets: 90 per cent vaccination coverage, 70 per cent screening coverage, and 90 per cent access to treatment for precancer and invasive cancer. Guyana’s national objectives mirror these benchmarks and demonstrate alignment with international best practice. Treatment capacity, ranging from visual inspection with acetic acid to chemotherapy and radiotherapy, with plans for a brachytherapy centre, signals a commitment to comprehensive care across the continuum of disease.
Under the Administration of Dr Irfaan Ali, the national commitment to eliminating cervical cancer by 2050 has been clearly articulated. Advocacy at the international level, including engagement through Guyana’s Permanent Mission in Geneva, reflects a recognition that elimination requires global solidarity. The proposal to accelerate worldwide elimination timelines draws a parallel with the eradication of smallpox, declared eliminated in 1980 following a coordinated vaccination campaign led by the World Health Organization. That historic achievement stands as evidence that sustained political will, scientific innovation and public cooperation can converge to defeat a once-devastating disease.
Expanded investment in education, integration of HPV awareness into school curricula, and collaboration with faith-based and community organisations are indispensable. Cultural sensitivities and misinformation continue to impede vaccine uptake in many societies. Transparent communication, grounded in science and delivered with respect for community values, is critical to overcoming resistance and building trust.
Eliminating cervical cancer would mark the first time a cancer has been ended globally. Such a milestone would signify a triumph for the power of prevention and early intervention.